Compare ADMA Biologics Inc (ADMA) vs Realty Income Corp (O) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Realty Income Corp — how do they compare? ADMA Biologics Inc trades at $9.2 (market cap $2.13B), while Realty Income Corp trades at $63.58 (market cap $59.69B). The key difference: Realty Income Corp is far larger — about 28× ADMA Biologics Inc's market cap, and Realty Income Corp pays a 5.08% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | O | |
|---|---|---|
Market Cap | $2.13B | $59.69B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $67.56 |
52-Week Low | $7.60 | $55.93 |
Enterprise Value | $2.20B | $89.49B |
Dividend Yield | — | 5.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Realty Income (O) trades at $64.01, up 0.27% with a bullish technical signal from moving averages. The REIT maintains strong fundamentals with $5.75B revenue (2025), 92.54% gross margins, and consistent monthly dividends. Recent earnings missed expectations for three consecutive quarters, but analyst consensus remains positive with a $67.86 price target. Operating cash flow grew to $4.0B in 2025, though debt-to-asset ratio increased to 39.93%.
Outlook remains stable with dividend reliability as a key strength, but elevated P/E (51.8) and recent earnings misses pose valuation concerns. Risks include rising leverage and interest rate sensitivity. Institutional sentiment leans bullish (41% buy ratings), supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
